公开(公告)号：US20180346556A1

公开(公告)日：2018-12-06

申请号：US15966247

申请日：2018-04-30

申请人： OncoMed Pharmaceuticals, Inc.

发明人： Robert Joseph STAGG ,  Steven Eugene Benner

IPC分类号： C07K16/18 ,  A61K39/395 ,  A61K31/166 ,  A61K31/341 ,  A61K31/401 ,  A61K31/4184 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61K31/138 ,  A61K39/00 ,  C07K16/22 ,  C07K16/24

CPC分类号： C07K16/18 ,  A61K31/138 ,  A61K31/166 ,  A61K31/341 ,  A61K31/401 ,  A61K31/4184 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  Y10S530/80 ,  Y10S530/86 ,  A61K2300/00

摘要： Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.

公开(公告)号：US20170166632A1

公开(公告)日：2017-06-15

申请号：US15336272

申请日：2016-10-27

申请人： OncoMed Pharmaceuticals, Inc.

发明人： Robert Joseph STAGG ,  Steven Eugene Benner

IPC分类号： C07K16/18

CPC分类号： C07K16/18 ,  A61K31/138 ,  A61K31/166 ,  A61K31/341 ,  A61K31/401 ,  A61K31/4184 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  Y10S530/80 ,  Y10S530/86 ,  A61K2300/00

摘要： Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.

公开(公告)号：US20160324961A1

公开(公告)日：2016-11-10

申请号：US15097631

申请日：2016-04-13

申请人： OncoMed Pharmaceuticals, Inc.

发明人： Robert Joseph STAGG ,  Steven Eugene BENNER ,  John LEWICKI ,  Timothy Charles HOEY

IPC分类号： A61K39/395 ,  A61K31/337 ,  A61K31/7068

CPC分类号： A61K39/3955 ,  A61K31/337 ,  A61K31/7068 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/22 ,  C07K2317/565

摘要： The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a DLL4 antagonist.

摘要翻译： 本发明提供了治疗癌症的方法。 更具体地，本发明提供了治疗癌症的方法，包括施用剂量的DLL4拮抗剂。

公开(公告)号：US20190023776A1

公开(公告)日：2019-01-24

申请号：US15762117

申请日：2016-09-23

申请人： OncoMed Pharmaceuticals, Inc.

发明人： Jakob DUPONT ,  Hema PARMAR ,  Robert Joseph STAGG

IPC分类号： C07K16/22 ,  A61P35/00 ,  C07K16/28 ,  C07K16/46 ,  A61K31/337

摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly pancreatic, colorectal, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., gemcitabine and ABRAXANE®; leucovorin, 5-fluorouracil, and irinotecan; and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a pancreatic, colorectal, or endometrial tumor. Also described are methods of treating cancer, particularly pancreatic, colorectal, and endometrial cancer, comprising administering a therapeutically effect amount of an agent, antibody, or therapeutic combination of the present invention to a patient having a tumor or cancer.